ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1587 • 2014 ACR/ARHP Annual Meeting

    The Economic Impact of Psoriatic Arthritis in Toronto, Ontario

    Dafna D. Gladman1,2, Melissa Yu1, Michal Bohdanowicz1, Arane Thavaneswaran3 and Vinod Chandran1,4, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: This study aimed to quantify the direct and indirect costs of psoriatic arthritis (PsA) at a single center in Toronto, Ontario and to assess…
  • Abstract Number: 1586 • 2014 ACR/ARHP Annual Meeting

    Quantitative Proteomic Analysis of Synovial Fluid and Skin Identifies Putative Psoriatic Arthritis Biomarkers

    Daniela Cretu1, Kun Liang2, Dafna D. Gladman3, Eleftherios Diamandis4 and Vinod Chandran3, 1Laboratory Medicine and Pathobiology, Unviersity of Toronto, Mount Sinai Hospital, Ontario, Canada, Toronto, ON, Canada, 2Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

    Background/Purpose Psoriatic arthritis (PsA) is a unique form of arthritis occurring in 30% of psoriasis patients. There is a high prevalence of undiagnosed PsA in…
  • Abstract Number: 1585 • 2014 ACR/ARHP Annual Meeting

    Presence of Swollen and Tender Joints in Patients Fulfilling Minimal Disease Activity Criteria

    Josefina Marin1, Maria L. Acosta Felquer2, Leandro Ferreyra-Garrot1, Santiago Ruta3, Javier Rosa1 and Enrique R. Soriano4, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2Internal Medicine, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 3Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina

    Background/Purpose Minimal disease activity (MDA) is a composite measure created for patients with psoriatic arthritis (PsA) that encompasses many clinically important aspects of PsA: arthritis,…
  • Abstract Number: 1584 • 2014 ACR/ARHP Annual Meeting

    Evaluation of the Patient Acceptable Symptom State in Patients with Psoriatic  Arthritis

    Pinar Cetin1, Dilek Solmaz2, Murat Keser3, Ismail Sari1, Merih Birlik1, Nurullah Akkoc1 and Fatos Onen1, 1Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, 2Department of Internal Medicine, Division of Rheumatology, Namik Kemal University School of Medicine, Tekirdag, Turkey, 3Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey

    Background/Purpose The Patient Acceptable Symptom State (PASS), a single-question outcome, has been defined as an absolute level of patient well-being, which was used in the…
  • Abstract Number: 1583 • 2014 ACR/ARHP Annual Meeting

    Screening for Psa in Primary Care Psoriasis Patients with Musculoskeletal Complaints with PEST, PASE & Earp

    M.C. Karreman1, A.E.a.M. Weel1,2, M. van der Ven1, M. Vis3, I. Tchetverikov4, M. Wakkee5, T.E.C. Nijsten5, J.M.W. Hazes1 and J.J. Luime1, 1Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 2Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 3Erasmus University Medical Center, Rotterdam, Netherlands, 4Albert Schweitzer Hospital, Dordrecht, Netherlands, 5Dermatology, Erasmus University Medical Center, Rotterdam, Netherlands

    Background/Purpose Psoriatic Arthritis (PsA) is a progressive inflammatory joint disease that can lead to severe joint damage. New treatment strategies can be very effective in…
  • Abstract Number: 1602 • 2014 ACR/ARHP Annual Meeting

    Th9 Cells in Inflammatory Cascades of Autoimmune Arthritis

    Siba Raychaudhuri1, Anupam Mitra2, Ananya Datta Mitra3, Christine Abria4 and Smriti K. Raychaudhuri3, 1Med/Rheumatology, Univ California Davis/VA Sac, Davis, CA, 2Dermatology, VA Sacramento Medical Center, Mather, CA, 3Rheumatology, VA Sacramento Medical Center, Mather, CA, 4Research, VA Sacramento Medical Center, Mather, CA

    Background/Purpose: Interleukin (IL)-9, a member of IL-2 cytokine family was recently attributed to a novel CD4 T cell subset termed Th9 cells in the murine…
  • Abstract Number: 1601 • 2014 ACR/ARHP Annual Meeting

    Are There Gender Specific Differences in Patient Characteristics at Initiation of Biologic Treatment in Ankylosing Spondylitis and Psoriatic Arthritis?

    John Kelsall1, William Bensen2, Wojciech Olszynski3, Niall Jones4, Isabelle Fortin5, Andrew Chow6, Milton Baker7, Saeed Shaikh8, Denis Choquette9, Emmanouil Rampakakis10, John S. Sampalis10, May Shawi11, Francois Nantel11, Susan Otawa12 and Allen J Lehman12, 1The Mary Pack Arthritis Centre, Vancouver, BC, Canada, 2St Josephs Hospital and McMaster University, Hamilton, ON, Canada, 3University of Saskatchewan, Saskatoon, SK, Canada, 4Dept of Rheumatology, University of Alberta, Edmonton, AB, Canada, 5Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, 6McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, 7University of Victoria, Victoria, BC, Canada, 8McMaster University, Hamilton, ON, Canada, 9Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Janssen Inc., Toronto, ON, Canada, 12Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose The prevalence of ankylosing spondylitis (AS) is 2-3 times higher in men compared to women whereas psoriatic arthritis (PsA) is generally considered a disease…
  • Abstract Number: 1600 • 2014 ACR/ARHP Annual Meeting

    Is There a Role for Inflammasome Activation in PsA Pathogenesis and Its Comorbidities?

    Rodolfo Perez Alamino1, Raquel Cuchacovich2, Arnold Zea3 and Luis R. Espinoza4, 1internal Medicine, LSUHSC, New Orleans, LA, 2Rheumatology, LSU Medical Center, New Orleans, LA, 3Stanley Scott Cancer Center, New Orleans, LA, 4Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA

    Background/Purpose . New data has emerged about the role of the inflammasome in psoriasis and psoriatic arthritis (PsA). The assembly of the inflammasome components in…
  • Abstract Number: 1563 • 2014 ACR/ARHP Annual Meeting

    Malignancies in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience

    David Fiorentino1, Mark Lebwohl2, Vincent Ho3, Richard Langley4, Kavitha Goyal5, Steve Fakharzadeh6, Steve Calabro5 and Wayne Langholff7, 1Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, 2Mount Sinai Medical Center, New York, NY, 3University of British Columbia, Vancouver, BC, Canada, 4Dalhousie University, Halifax, NS, Canada, 5Janssen Services, LLC, Horsham, PA, 6Janssen Services, LLC, Spring House, PA, 7Janssen Research and Development, LLC, Spring House, PA

    Background/Purpose To report the cumulative incidence of malignancies excluding non-melanoma skin cancers (NMSC) in the PSOLAR study. Methods PSOLAR is a multicenter, longitudinal, observational study…
  • Abstract Number: 1578 • 2014 ACR/ARHP Annual Meeting

    Abatacept Improves Synovitis As Assessed By Magnetic Resonance Imaging (MRI) in Psoriatic Arthritis – Preliminary Analysis from a Single Centre, Placebo-Controlled, Crossover Study

    Agnes Szentpetery1, Eric J. Heffernan2, Muhammad Haroon3, Phil Gallagher1, Anne-Marie Baker1, Martina Cooney1 and Oliver FitzGerald1, 1Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, 2Radiology, St. Vincent's University Hospital, Dublin, Ireland, 3Newmarket On Fergus, Cork University Hospital, Cork, Ireland

    Background/Purpose Abatacept is a soluble, fully human fusion protein which selectively inhibits T-cell activation via the CD80/CD86:CD28 co-stimulation pathway and decreases serum levels of inflammatory…
  • Abstract Number: 1577 • 2014 ACR/ARHP Annual Meeting

    Value and Prediction of Minimal Disease Activity in Patients with Psoriatic Arthritis

    Arthur Kavanaugh1, Philip J. Mease2, Laura C. Coates3, Iain B. McInnes4, Maja Hojnik5, Alex Dorr6, Ying Zhang6, Benoit Guerette6, Alan Friedman6 and Dafna D. Gladman7, 1University of California San Diego, La Jolla, CA, 2Swedish Medical Center and University of Washington, Seattle, WA, 3NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 4Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 5AbbVie, Ljubljana, Slovenia, 6AbbVie, Inc., North Chicago, IL, 7University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose The prediction of treatment outcomes based on early response could be useful in guiding decisions to adjust therapy. The objective was to determine if…
  • Abstract Number: 1576 • 2014 ACR/ARHP Annual Meeting

    Reversal of Damage in Psoriatic Arthritis

    Amir Haddad1, Ker-Ai Lee2, Arane Thavaneswaran1, Vinod Chandran1, Richard J. Cook2 and Dafna D. Gladman1, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada

    Background/Purpose Psoriatic arthritis could lead to severe damage and disability. However, cases of improvement in joint damage over time have been reported in the literature.…
  • Abstract Number: 1575 • 2014 ACR/ARHP Annual Meeting

    The Association Between Obesity and Disease Phenotype in Psoriatic Arthritis

    Lihi Eder1, Cheryl Rosen2, Vinod Chandran3 and Dafna D. Gladman3, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Division of Dermatology, University of Toronto, Toronto western Hospital, Toronto, ON, Canada, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Obesity is associated with an increased risk of developing psoriatic arthritis (PsA) in patients with psoriasis. This study aimed to assess whether obesity is…
  • Abstract Number: 1573 • 2014 ACR/ARHP Annual Meeting

    Norwegian Psoriatic Arthritis Patients Are More Obese Than Rheumatoid Arthritis and Axial Spondyloarthropathy Patients

    Brigitte Michelsen1, Andreas P. Diamantopoulos2, Arthur Kavanaugh3 and Glenn Haugeberg1,4, 1Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 2Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 3University of California San Diego, La Jolla, CA, 4Faculty of Health and Sport Sciences, University of Agder, Kristiansand, Norway

    Background/Purpose Higher rates of obesity in psoriatic arthritis (PsA) compared to rheumatoid arthritis (RA) have been described. Obesity, C-reactive protein (CRP) and inflammatory arthritides itself…
  • Abstract Number: 1572 • 2014 ACR/ARHP Annual Meeting

    Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial

    Christopher J. Edwards1, Jacob A. Aelion2, Adewale O. Adebajo3, Alan Kivitz4, Paul Bird5, ChiaChi Hu6, Randall M. Stevens6 and Alvin Wells7, 1University Hospital Southampton, Southampton, United Kingdom, 2West Tennessee Research Institute, Jackson, TN, 3University of Sheffield, Sheffield, United Kingdom, 4Altoona Arthritis & Osteoporosis Center, Duncansville, PA, 5Combined Rheumatology Practice, Kogarah, Australia, 6Celgene Corporation, Warren, NJ, 7Rheumatology & Immunotherapy Center, Franklin, WI

    Background/Purpose: Apremilast (APR) is a phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA).…
  • « Previous Page
  • 1
  • …
  • 1944
  • 1945
  • 1946
  • 1947
  • 1948
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology